Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase Ib/II clinical trial (SYS 6090 -008) of the SYS 6090 injection combination treatment plan developed by the group for the treatment of colorectal cancer has been officially launched at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.